Peripheral Neuropathy in Macroglobulinemia:Incidence & Antigen-Specificity of M Proteins
Neurol 37:1506-1514, Nobile-Orazio,E.,et al, 1987
Peripheral Neuropathy Associated with Monoclonal IgM Autoantibody
Ann Neurol 22:764-767, Steck,A.J.,et al, 1987
Proximal Motor Neuropathy, Dermato-Endocrine Syndrome, & IgGk Paraproteinemia
Arch Neurol 43:845-848, Berkovic,S.F.,et al, 1986
Motor Neuron Disease & Plasma Cell Dyscrasia
Neurol 36:1429-1436, Shy,M.E.,et al, 1986
Chronic Idiopathic Ataxic Neuropathy
Ann Neurol 19:545-554, Dalakas,M.C., 1986
Gammopathy with Proximal Motor Axonopathy Simulating Motor Neuron Disease
Neurol 36:273-276, Parry,G.J.,et al, 1986
Treatment of Peripheral Neuropathies
JNNP 48:1193-1207, Hallett,M.,et al, 1985
Polymyositis Associated with Monoclonal Gammopathy
Lancet 2:1183-1186, Kiprov,D.D.,et al, 1984
Osteosclerotic Myeloma & Peripheral Neuropathy
Neurol 33:202-210, Kelly,J.J.,et al, 1983
Polyneuropathy in Nonmalignant IgM Plasma Cell Dyscrasia:A Morphological Study
Ann Neurol 14:43-54, Nemni,R.,et al, 1983
Treatment of Polyneuropathy in Waldenstrom's Macroglobulinemia:Role of Paraproteinemia & Immunologic Studies
Neurol 33:1406-1410, Dalakas,M.C.,et al, 1983
Peripheral Neuropathy with IgM Kappa Monoclonal Immunoglobulin Directed Against Myelin-Associated Glycoprotein
Neurol 33:1397-1405, Melmed,C.,et al, 1983
Amyotrophic Lateral Sclerosis & Paraproteinemia
Neurol 32:896-898, Krieger,C.,et al, 1982
Polyneuropathy with Monoclonal Gammopathy:Studies of 11 Patients
Ann Neurol 10:45-52, Dalakas,M.C.,et al, 1981
Plasma-Cell Dyscrasia & Peripheral Neuropathy With A Monoclonal Antibody To Peripheral-Nerve Myelin
NEJM 303:618-621, Latov,N.,et al, 1980
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis
NEJM 392:2062-2064, Koster,M.J. & Warrington,K.J., 2025
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Clinical Presentation, Management, and Outcome in Neurolymphomatosis, A Systematic Review
Neurol 103:e209698, Kaulen.L.D.,et al, 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Diagnosis and Management of ANCA-Associated Vasculitis
Lancet 403:683-698, Kronbichler, A., et al, 2024
Progressive Hemiparesis and White Matter Abnormalities in an HIV-Negative Patient
Neurol 100:1156-1163, Jabbari,E.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Lecanemab, Looking Before We Leap
Neurol 101:661-665, Burke,J.F.,et al, 2023
Polymyalgia Rheumatica
Lancet 402:1459-1472, Espigol-Frigole,G.,et al, 2023
Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023
A 60-Year Old Man with Asymmetric Weakness and Persistent Fever
Neurol 100:530-536, Zheng,Y.,et al, 2023
Amyloid-Related Imaging Abnormalities:An Update
AJR 220:562-575, Roytman,M.,et al, 2023
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Atypical Presentation of Primary Angiitis of Central Nervous System Responsive to Rituximab
Stroke 53:e490-e494, Kesav, P.,et al, 2022
A 48-Year-Old Woman with 6 Months of Vivid Visual Hallucinations
Neurol 99:166-171, Kizza, J.,et al, 2022
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Progressive Vertebrobasilar Vasculopathy and Stroke Secondary to Giant Cell Arteritis
Stroke 53:e435-e438, Mahjoub, Y.,et al, 2022
Clinicopathologic Conference, Encephalitis due to Behcets Disease
NEJM 387:925-933, Case 27-2022, 2022
Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients with Early Alzheimer Disease
Neurol 98:e968-e977, Whittington, M.D.,et al, 2022
Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022
Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis
Neurol 98:e2368-e2376, Molimard, A.,et al, 2022
A New Option is Approved for Patients with Myasthenia Gravis
JAMA 327:417, Voelker, R., 2022
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Drugs Associated with Ischemic Stroke
Stroke 52:e646-e659, Marto, J.P.,et al, 2021
Pembrolizumab-Induced Migrating Cortico-Subcortical Brain Lesions
Ann Neurol 89:1255-1256, Lambert, N.,et al, 2021
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021